◼ Archived
Business
🔮 holds ✗
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
2 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 1 news category, from Jul 7, 2026 through Aug 18, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
Democratic lawmakers are investigating Howard Lutnick over a $1.6 billion deal involving Cantor Fitzgerald and USA Rare Earth.